Dr. Ray Page and ASCO CEO Dr. Clifford Hudis discuss Pharmacy Benefit Managers (PBMs) on the ASCO in Action Podcast. Dr. Page feels PBMs’ original intent was good, but over time that’s changed. “They claim that they’re controllers of cost,” he says, “but in reality, they have created huge and extremely complex business relationships to where they now have put personal profits ahead of patients.”
A new ASCO position statement describes practices used by pharmacy benefit manager (PBM) companies that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right care at the right time for people with cancer. ASCO also recommends a series of actions to address PBM practices that interfere with the delivery of prescribed therapies.
Findings published in the Journal of Clinical Oncology indicate patients with untreated non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFRm) and with central nervous system (CNS) metastases at baseline were reported to have better CNS outcomes when treated with osimertinib compared with the first-generation EGFR tyrosine kinase inhibitors (TKIs).
ASCO Symposia bring together specialists from around the world to offer educational content and the latest scientific discoveries in the respective fields, while providing ample time for networking and collaboration. Upcoming Symposia include the Palliative and Supportive Care in Oncology Symposium, Gastrointestinal Cancers Symposium, Cancer Survivorship Symposium: Advancing Care in Research, Genitourinary Cancers Symposium and more.